Компания XM не предоставляет услуги резидентам Соединенных штатов Америки.
L
L

Lonza


Новости

Swiss trade surplus at CHF 4.946 bln in September

TABLE-Swiss trade surplus at CHF 4.946 bln in September Oct 17 (Reuters) - Switzerland ran a merchandise trade surplus of 4.946 billion Swiss francs in September, the Federal Customs Office said on Thursday. KEY FIGURES (millions of Swiss francs) September 2024 August 2024 Imports 17.579 15.905 Exports 22.526 20.649 Balance 4.946 4.744 The figures exclude precious metals and stones, works of art and antiques.
C
L
N
R
R
S

Top of the Street: ING, Lonza, Repsol

BUZZ-Top of the Street: ING, Lonza, Repsol A round-up of notable broker activity this morning from Europe's top-ranked* analysts: ** Deutsche Bank cuts ING INGA.AS to "hold" from "buy" saying it expects less support from the Dutch lender's large but relatively short replicating portfolio going forward; it sees falling revenues next year while cost inflation will likely remain elevated, resulting in efficiency deterioration in 2025 ** Exane BNP Paribas downgrades Repsol REP.MC to "neutral" from "
I
L
R

Lonza And Vertex Sign A Supply Agreement For Casgevy®

BRIEF-Lonza And Vertex Sign A Supply Agreement For Casgevy® Sept 24 (Reuters) - LONZA GROUP AG LONN.S : LONZA AND VERTEX SIGN A LONG-TERM COMMERCIAL SUPPLY AGREEMENT FOR CASGEVY® (EXAGAMGLOGENE AUTOTEMCEL) LONZA GROUP AG - TO MANUFACTURE WORLD'S FIRST CRISPR/CAS9 CELL THERAPY LONZA GROUP AG - GELEEN (NL) SITE IS NOW APPROVED BY FDA, EMA AND MHRA
L

Swiss trade surplus at CHF 4.578 bln in August

TABLE-Swiss trade surplus at CHF 4.578 bln in August Sept 19 (Reuters) - Switzerland ran a merchandise trade surplus of 4.578 billion Swiss francs in August, the Federal Customs Office said on Thursday. KEY FIGURES (millions of Swiss francs) August 2024 July 2024 Imports 15.912 19.215 Exports 20.491 24.092 Balance 4.578 4.877 The figures exclude precious metals and stones, works of art and antiques.
C
L
N
R
R
S

Stifel adjusts ratings on European pharma; downgrades Sartorius, Siegfried ahead of H2

BUZZ-Stifel adjusts ratings on European pharma; downgrades Sartorius, Siegfried ahead of H2 ** Stifel shares thoughts on European pharmaceutical companies heading into H2; downgrades Sartorius SATG.DE and Siegfried SFZN.S to "hold", citing concerns over growth catalysts and valuation alignment with recent strong performance ** The analyst flags the
L

Alstom, Siemens, Tesco

EUROPE RESEARCH ROUNDUP-Alstom, Siemens, Tesco Sept 13 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Alstom, Siemens and Tesco, on Friday. HIGHLIGHTS * Alstom ALSO.PA : HSBC raises target price to EUR 26 from EUR 24 * Hexagon AB HEXAB.ST : HSBC cuts target price to SEK 110 from SEK 120 * Siemens AG SIEGN.DE : HSBC cuts target price to EUR 140 from EUR 150 * Tesco TSCO.L : Citigroup raises target price to 425p from 350p * Travis P
A
A
A
B
B
B
C
C
C
D
D
E
E
F
H
H
I
K
L
L
S
S
S
S
T
T
P
A
A
F
S
U

Swiss stocks - Factors to watch on September 13

Swiss stocks - Factors to watch on September 13 ZURICH/GDANSK, Sept 13 (Reuters) - Here are some of the main factors that may affect Swiss stocks on Friday: A survey of Swiss banks has highlighted international sanctions imposed on other countries, such as against Russia over Ukraine, as the greatest geopolitical risk to their business. ANALYSTS' VIEWS ABB ABBN.S - HSBC RAISES TARGET PRICE TO CHF 45 FROM CHF 43 ALCON ALCC.S - HSBC CUTS TARGET PRICE TO CHF 89 FROM CHF 91 LONZA LONN.S - HSBC RAISE
A
L
S
S

Swiss stocks - Factors to watch on August 29

Swiss stocks - Factors to watch on August 29 ZURICH/GDANSK, Aug 29(Reuters) - Here are some of the main factors that may affect Swiss stocks on Thursday: Swiss court convicts two executives over $1.8 billion 1MDB fraud The Swiss Federal Criminal Court convicted on Wednesday two executives at an oil exploration company for embezzling more than $1.8 billion from Malaysia's state investment fund 1MDB.
L
S

Lonza Says Co Prices EUR 1.2 Bln Dual-Tranche Straight Bonds

BRIEF-Lonza Says Co Prices EUR 1.2 Bln Dual-Tranche Straight Bonds Aug 28 (Reuters) - Lonza Group AG LONN.S : LONZA PRICES EUR 1.2 BILLION DUAL-TRANCHE STRAIGHT BONDS LONZA GROUP - BONDS FOR LONZA FINANCE INTERNATIONAL HAVE MATURITY OF 6 AND 10 YEARS WITH COUPONS OF 3.25% AND 3.50% RESPECTIVELY Source text for Eikon: ID:nEQbznFm8a Further company c
L

Greencore, UCB, Unilever

EUROPE RESEARCH ROUNDUP-Greencore, UCB, Unilever July 26 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Greencore, UCB, and Unilever, on Friday. HIGHLIGHTS * Greencore GNC.L : HSBC raises target price to 190p from 160p * Lonza Group AG LONN.S : JP Morgan raises target price to CHF 645 from CHF 600 * Sartorius Stedim Biotech STDM.PA : HSBC cuts target price to EUR 310 from EUR 360 * UCB SA UCB.BR : TD Cowen raises target price to E
A
A
A
B
B
B
B
B
C
D
D
E
G
G
G
L
N
N
P
R
S
U
A
A
A
A
A
A
B
D
J

Swiss stocks - Factors to watch on July 26

Swiss stocks - Factors to watch on July 26 July 26 - Here are some of the main factors that may affect Swiss stocks on Friday: HOLCIM HOLN.S Reports Q2 results slightly ahead of forecasts. COMPANY STATEMENTS AMS OSRAM AMS.S Second quarter earnings release due. FORBO HOLDING FORN.S Confirms spring outlook for full year 2024. VONTOBEL VONN.S Half-year earnings release due.
A
L
N
S
J

European shares fall as earnings deluge disappoints

UPDATE 2-European shares fall as earnings deluge disappoints STOXX 600 down 0.7% Universal Music Group slumps as streaming growth disappoints Kering down after weak H2 forecast Besi tumbles as Q3 outlook disappoints Unilever gains after H1 profit beat Updated at 1600 GMT By Pranav Kashyap and Shashwat Chauhan July 25 (Reuters) - European shares closed lower on Thursday as a slate of downbeat earnings reports in several sectors including tech and luxury weighed, while a global run for safe haven
K
L
N
R
R
S
A
E
F
U
G

Swiss pharma firm Lonza hits 1-year high on earnings beat

BUZZ-Swiss pharma firm Lonza hits 1-year high on earnings beat Updates share move, adds milestone ** Shares in Lonza LONN.S jump 8% to their highest level in a year after the Swiss contract drug manufacturer's H1 core earnings fell less than expected by the market ** The stock tops the broad Swiss blue-chip index .SSMI , which was down 0.5% by 0717
L
S

Swiss pharma firm Lonza seen up on smaller-than-expected earnings drop

BUZZ-Swiss pharma firm Lonza seen up on smaller-than-expected earnings drop ** Shares in Swiss contract drug manufacturer Lonza LONN.S are seen rising 3.5% in the Julius Baer premarket indications after its H1 core earnings fell less than expected by the market ** H1 adjusted EBITDA fell to 893 million Swiss francs ($976.4 million), vs 802 million
L
J

Swiss pharma firm Lonza's profit falls less than feared, shares rise

UPDATE 3-Swiss pharma firm Lonza's profit falls less than feared, shares rise Rewrites with details on shares, adds analyst comment, details on Biologics unit, background; paragraphs 1-4 By Isabel Demetz and Andrey Sychev July 25 (Reuters) - Swiss contract drug manufacturer Lonza LONN.S reported a smaller-than-expected decline in first-half profit on Thursday, as a strong performance in its core Biologics unit partly offset weak demand for capsules.
C
L
S

Swiss pharma supplier Lonza reports lower half-year results

Swiss pharma supplier Lonza reports lower half-year results July 25 (Reuters) - Swiss contract drug manufacturer Lonza LONN.S reported a drop in its half year profit, hurt by lacklustre demand in its capsules and health ingredients businesses, but beat market estimates, it said on Thursday. It reported an adjusted core earnings before interest, taxes, depreciation and amortization (EBITDA) of 893 million Swiss francs ($976.4 million), compared to 922 million Swiss francs a year earlier.
L

Swiss stocks - Factors to watch on July 25

Swiss stocks - Factors to watch on July 25 ZURICH/GDANSK, July 25(Reuters) - Here are some of the main factors that may affect Swiss stocks on Thursday: COMPANY STATEMENTS DORMAKABA DOKA.S Dormakaba expands production in India. LEONTEQ LEON.S Leonteq says outlook for 2024 is reaffirmed. BUCHER INDUSTRIES AG BUCN.S Bucher Industries says group expects lower sales in 2024. BACHEM HOLDING AG BANB.S Half-year results due.
L
N
R
S
J
S



Условия

Попул. активы

Правовая оговорка: Компании группы XM Group предоставляют только услуги по исполнению сделок и доступ к нашей торговой онлайн-среде, в которой пользователи могут просматривать и (или) пользоваться материалами, доступными на вебсайте либо доступными по ссылкам с данного сайта на другие. Предоставление доступа к онлайн-среде не меняет сути предоставляемых услуг и не расширяет их. Такой доступ и пользование материалами предоставляются с учетом:(i) «Условий и положений»; (ii) «Предупреждений о рисках» и (iii) полного текста «Правовой оговорки». Следовательно, подобные материалы предоставляются лишь в качестве информации общего характера. В частности, просим Вас иметь в виду, что материалы, содержащиеся в нашей торговой онлайн-среде, не являются ни просьбой осуществить какие-либо транзакции на финансовых рынках, ни предложением к осуществлению подобных транзакций. Торговля на любом финансовом рынке подразумевает большой риск потери Вашего капитала.

Все материалы, опубликованные в нашей торговой среде, предоставляются только в образовательных или информационных целях и не содержат (и не должны рассматриваться как содержащие) финансовых, инвестиционных или торговых рекомендаций, а также информации о стоимости наших услуг по предоставлению доступа к рынкам, либо предложения или содействия в проведении транзакций по какому-либо финансовому инструменту или по незапрашиваемым финансовым услугам по отношению к Вам.

Любые материалы на данном вебсайте, созданные третьими лицами, а также материалы, подготовленные XM, такие как мнения экспертов, новости, исследования, анализ, котировки и другая информация, а также ссылки на сторонние сайты предоставляются в виде «как есть», как рыночная информация общего характера, и не являют собой рекомендации по инвестициям. Принимая во внимание то, что любые материалы рассматриваются как инвестиционное исследование, Вам следует учесть и принять тот факт, что никакие материалы не подготавливались и не предназначались к использованию в соответствии с правовыми нормами, способствующими независимости инвестиционных исследований. Следовательно, материалы следует рассматривать как материалы рекламного характера согласно соответствующим законам и правовым нормам. Рекомендуем Вам прочесть и уяснить для себя положения наших «Уведомления о субъективном инвестиционном исследовании» и «Предупреждения о рисках» в отношении приведённой выше информации. С этими документами можно ознакомиться здесь.

Предупреждение о риске. Вы рискуете потерять свой капитал. Торговля маржинальными продуктами подходит не всем инвесторам. Пожалуйста, ознакомьтесь с нашим Предупреждением о рисках.